#EHA2024: Indolent and mantle cell NHL

To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Hybrid Congress, we have collated our social media coverage. Catch up with our live social media relating to indolent and mantle cell NHL, here.

CONGRESS #EHA2024 | Late-breaking | @michaelwangmd @MDAndersonNews reports phase 3 ECHO trial of acalabrutinib (A) plus bendamustine (B) and rituximab (R) vs placebo (P) BR in untreated MCL. N=598, mFU=17 mo, mPFS=66.4 mo & 49.6 mo with ABR & PBR, resp; P=0.0160. OS was positive… pic.twitter.com/Fmlqe3JVDF

— Lymphoma Hub (@lymphomahub) June 16, 2024

CONGRESS #EHA2024 | Umberto Vitolo reports 1st results from EPCORE NHL-1 FL cycle 1 optimization (C1 OPT) cohort investigating mitigation strategies for CRS with no mandatory hospitalization in pts with R/R FL receiving epcoritamab. N=86, primary endpoint, reduction in CRS, met… pic.twitter.com/iAgDBcBrBn

— Lymphoma Hub (@lymphomahub) June 15, 2024

CONGRESS #EHA2024 | Sarit Assouline presents subgroup analysis of phase II study evaluating mosunetuzumab monotherapy in high-risk pts with heavily pre-treated R/R FL. Durable remissions and clinically meaningful survival outcomes observed, including those with POD24 (3-year PFS… pic.twitter.com/415B2bVHnB

— Lymphoma Hub (@lymphomahub) June 15, 2024

CONGRESS #EHA2024 | Tycel Phillips, MD (@LymphClinician) from @cityofhope presented an updated analysis of the phase I/II study of glofitamab for R/R #mantlecelllymphoma, demonstrating high response rates and durable responses in both BTKi-treated and -naïve pts. Majority of… pic.twitter.com/lMBPEAz4nS

— Lymphoma Hub (@lymphomahub) June 15, 2024

CONGRESS #EHA2024 | Primary analysis of the phase II ELM-2 study demonstrates deep and durable responses with odronextamab (CD20×CD3 bispecific antibody) in heavily pretreated pts with R/R FL. Primary endpoint ORR, 80%; CR rate 73%; CR correlated with favorable PFS and OS at 24… pic.twitter.com/L302fO0fGL

— Lymphoma Hub (@lymphomahub) June 15, 2024

CONGRESS | #EHA2024
Enrico Tiacci, University of Perugia, presents findings from the HCL-PG04 phase II trial of obinutuzumab monotherapy and combination with vemurafenib in patients with R/R hairy cell leukemia.
▪️ Safety profile of obinutuzumab as expected, mostly grade 1 (n=26)… pic.twitter.com/jR6Hje03Y9

— Lymphoma Hub (@lymphomahub) June 16, 2024